TABLE 1 

In vitro antifungal activities of N′-(3-bromo-4-hydroxybenzylidene)-2-methylbenzohydrazide (BHBM) determined by the MICs against several fungal clinical isolates and reference strains

Species (straina) (n)MIC range (µg/ml)
Cryptococcus neoformans (FTL strains) (13)0.25−8
Cryptococcus neoformans (MDPL strains and S isolates) (8)0.5−2
Cryptococcus neoformans (MDPL strains and R isolates) (4)1−2
Cryptococcus gattii (FTL strains) (10)0.5−2
Cryptococcus gattii (MDPL strains) (3)0.5−1
Candida albicans (FTL strains) (3)>32
Candida albicans (MDPL strains) (5)>32
Candida krusei (MDPL strain) (1)32
Candida krusei ATCC 6258 (MDPL strain)16
Candida krusei QC FTL strains8
Candida glabrata (FTL strains) (10)0.125−2
Candida glabrata (MDPL strains) (3)4−>32
Candida parapsilosis (MDPL strains) (3)>32
Candida parapsilosis QC FTL strains>16
Candida guilliermondii (FTL strains) (3)2−>16
Aspergillus fumigatus (MDPL strain) (1)8
Aspergillus fumigatus (FTL strains) (3)>16
Rhizopus oryzae (FTL strains) (3)2
Blastomyces dermatitis (FTL strains) (10)0.5−1
Histoplasma capsulatum (FTL strains) (10)0.125−1
Coccidioides spp. (FTL strains) (10)8–16
Paecilomyces variotii QC FTL strains>16
  • a FTL strains, strains from the Fungus Testing Laboratory at the University of Texas Health Science Center at San Antonio; MDPL strains, strains from Maurizio Del Poeta's laboratory. S isolates, clinical isolates sensitive to fluconazole; R isolates, clinical isolates resistant to fluconazole; QC, quality control.